Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。

サイズ 価格(税別)  
JPY 30710.00
JPY 18260.00
JPY 28220.00
JPY 61420.00
JPY 161020.00

カスタマーフィードバック(4)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3は一種の有効で、選択性的なMdm2 (自身とp53に対するRING finger-dependent ubiquitin protein ligase) 拮抗剤で、無細胞試験でIC50値が90 nMですが、p53欠陥細胞中のp73を安定させられます。
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M1WzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj0OeKh|ryP M1rNTVQ5yqCq MVLicI9kc3NiMketU2hENWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDhdoFjdGVidH:geIhifCCxZjDiZZNidCCuZY\lcJM> NVrPbHdlOjZ|NUC1OlU>
NP69 NV7TO414T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTNzLk[5xtEzNjV2IN88US=> NHfjNm0zPjJ3MkW3OS=>
NP460 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3GZoRKSzVyPUKyMlg2yrFzLkG4JO69VQ>? MV:yOlI2OjV5NR?=
C666-1 NWPkd21mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16xfmlEPTB;MUmuPVXDuThwOUOg{txO NYexUmhmOjZ{NUK1O|U>
C666-1 M2TyXWNmdGxiVnnhZoltcXS7IFHzd4F6 M3zrfVExKML3TR?= NX;LUYZoPDhiaB?= MmnnSG1UVw>? MV3z[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzD0bIUh[3m2b4TvfIlkKGWoZnXjeEBw\iClaYPwcIF1cW5? M{i1TVI3OjV{NUe1
C666-1  M13PO2Z2dmO2aX;uJGF{e2G7 NHzZRY8yOCEEtV2= NYfodWdSOjRiaB?= M1jBemROW09? NUD1dmFv[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ MmrFNlYzPTJ3N{W=
C666-1 NVXqO4JvSXCxcITvd4l{KEG|c3H5 M375blExKML3TR?= MVy0PE84OiCq MYLEUXNQ NHmydmt{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NXHPVXFZOjZ{NUK1O|U>
A549 NX;yTlhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrXNlQhcA>? MVTJR|UxRTF5Lk[4JOKyKDRwNUKg{txO MXuyOlEzPTJ|MB?=
A549-NTC NXnvWXY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2yUVNtOjRiaB?= M1rTfmlEPTB;MUmuOFIhyrFiMT65OkDPxE1? NF\ZNWEzPjF{NUKzNC=>
A549-920 NV\GO441T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WxcFI1KGh? NVHXfmNRUUN3ME2zN{45PSEEsTC0Mlg1KM7:TR?= NVHYXm45OjZzMkWyN|A>
CRL-5908 NVjkTHBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP1N5g5OjRiaB?= M33obGlEPTB;M{iuO|EhyrFiMj60N{DPxE1? MUWyOlEzPTJ|MB?=
L6 M4nvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLPTY8yOMLizszNxsA> MXmyOE81QC95MjDo M2W3WmROW09? M333N4lvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? MUiyOVg4OTd7NB?=
C2C12 NWXtNW1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7LblUyOMLizszNxsA> MUKyOE81QC95MjDo MXzEUXNQ NEC0XIVqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? M3T2NlI2QDdzN{m0
MCF-7  NFnCXlJHfW6ldHnvckBCe3OjeR?= MWGxNOKh|ryP MW\EUXNQ NXnFUYg1cW6qaXLpeJMh[3mlbHnuJGQyKGGwZDDEbYNmesLi NFzIfmwzPTdyMkewNy=>
DU4475  MVTGeY5kfGmxbjDBd5NigQ>? NVvOZ5F[PS9zMD:yNEDPxE1? NUHZ[49uOjUEoHi= NHfIOopld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 NF7zdoMzPTV2N{G3OC=>
SMMC-7721 NEX3UZVHfW6ldHnvckBCe3OjeR?= MoX6NVAh|ryP MnHUOFghcA>? NVPLOWxHTE2VTx?= NHfLWmFk[XW|ZYOgSG5CKESVQjDkZY1i\2V? Ml33NlU2PDR|NkG=
SMMC-7721 MkTLSpVv[3Srb36gRZN{[Xl? Mki4NVAh|ryP MWW0PEBp NFWwPZVFVVOR MmjZbY5lfWOnczD0bIUh[2i{b33heIlvNWKxdX7kJJBzd3SnaX6gTWZKOTZidH:gdIFzfGmjbHz5JIxw[2GuaYrlJIlvKHSqZTDjfZRweGyjc35CpC=> M1zI[lI2PTR2M{[x
SMMC-7721 MUPGeY5kfGmxbjDBd5NigQ>? MVSxNEDPxE1? NYrKZ5pNPDhiaB?= M3fKWGROW09? MX;pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7B MXOyOVU1PDN4MR?=
SMMC-7721 M1\0VmZ2dmO2aX;uJGF{e2G7 MWKxNEDPxE1? M2\5[lM3KGh? NWf6fXNGTE2VTx?= Mn7ZZ4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> NYjkZVdHOjV3NESzOlE>
MCF-7 MlvQSpVv[3Srb36gRZN{[Xl? NFX4UIMyOMLizszN MmrlNE0zPCCq NY[3[4NkcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx NV3KfFVCOjV2OEKzO|M>
OVCAR10 MV\GeY5kfGmxbjDBd5NigQ>? NIi5SWIyOMLizszN MkXMNlFpyqB? MlGxSG1UVw>? Mk\TbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> NUf1NmNWOjV2Mk[1OFg>
NCI-H23 M3\pbWZ2dmO2aX;uJGF{e2G7 NG\pc4wyOMLizszN MlnuNlFpyqB? NX3XOpI6TE2VTx?= MVfpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz Mn33NlU1OjZ3NEi=
A2780 M4fncGZ2dmO2aX;uJGF{e2G7 NUfZTJIzOTEEoN88US=> MlnqNlFpyqB? M{\CcWROW09? MULpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz MlXsNlU1OjZ3NEi=
NCI-H23 NXe5elFKTnWwY4Tpc44hSXO|YYm= M3\OelExyqEQvF2= M2DtdFIycMLi NUG4[pVWTE2VTx?= MWXk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= NHKwUmszPTR{NkW0PC=>
A2780 M3LQc2Z2dmO2aX;uJGF{e2G7 NX[zXFdzOTEEoN88US=> M3HNfVIycMLi M4HhNWROW09? NGnrZVRl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> M2rUUlI2PDJ4NUS4
HCT116  M3y1[2Z2dmO2aX;uJGF{e2G7 MYixNEDDvU1? M1HqTlI1KGh? MkDtZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 NGXnR2kzPTN6MEC1OS=>
MCF-10CA1a NYPQTVZZTnWwY4Tpc44hSXO|YYm= Mn;JNVDDqM7:TR?= MX[0PEBp M3X4R2ROW09? M324[4lvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? MoTkNlUzPTd5Mkm=
MCF-10A1  MWjGeY5kfGmxbjDBd5NigQ>? MXyxNOKh|ryP MXOyOE81QCCq MYTEUXNQ MojRbY5pcWKrdIOgcYloemG2aX;uJI9nKG6xcn3hcEBjemWjc4Sg[ZBqfGinbHnhcOKh MnHrNlUzPTd5Mkm=
MCF-10CA1a M1[3U2Z2dmO2aX;uJGF{e2G7 NEHD[5YyOMLizszN M4HsWlI1KGh? MkTESG1UVw>? M4TJVYRm[3KnYYPld{B1cGViVFfGMe6zOy2rbnT1Z4VlKG2UTlGgcIV3\Wy|IH;mUW1ROi{EoF3NVFktKGGwZNMgbY51\We{aX9CpO6zyqB| M3jWRlI2OjV5N{K5
MCF-10CA1a MYjGeY5kfGmxbjDBd5NigQ>? M1nhSVExyqEQvF2= M4Ll[FI1KGh? NYqzdYJITE2VTx?= M2ez[YlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= MoXKNlUzPTd5Mkm=
SK-BR-7 NEX2NoZHfW6ldHnvckBCe3OjeR?= NFLOOGsyOMLizszN NFXnN3QzPCCq NXTLc25ITE2VTx?= MWfpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MnvsNlUzPTd5Mkm=
SUM102PT MnPJSpVv[3Srb36gRZN{[Xl? MXqxNOKh|ryP MVWyOEBp MoHWSG1UVw>? NYPuVnQ1cW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u MVGyOVI2Pzd{OR?=
RAW 264.7 MlHwSpVv[3Srb36gRZN{[Xl? MVyxNOKh|ryP M3;z[|MxKG2rbh?= NFfRNmpxemW4ZX70d{B1cGVicEWzJJJm\HWldHnvckBqdiC{ZYPwc45{\SC2bzDMVHM> MV2yOVE4OjV2Nx?=
RAW 264.7 MVvGeY5kfGmxbjDBd5NigQ>? NETselIyOMLizszN MoLRN|AhdWmw NXH2bWVwemWmdXPld{B1cGViTGDTMYF2\22nboTl[EB1cGViTl[t{tpDKGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBi[3Srdnn0fS=> MnPJNlUyPzJ3NEe=
RAW 264.7 MmKySpVv[3Srb36gRZN{[Xl? NV34R4FKOTEEoN88US=> M{TvRVMxKG2rbh?= MYrpcohq[mm2czDMVHMucW6mdXPl[EBPVyCycn;keYN1cW:wwrC= NVX6TJJ7OjVzN{K1OFc>
MCF7  Mn22R4VtdCCYaXHibYxqfHliQYPzZZk> MUeyMlUhyrWP M2\FRVUh\A>? NVLjcHhFTE2VTx?= MXrz[Y5{cXSrenXzJG1ETjdidH:gVGFTWCCrbnjpZol1cW:w M3XFW|I2ODh3OUCy
MCF7  M37KR2Z2dmO2aX;uJGF{e2G7 MXqyMlUhyrWP MmnHOFghcA>? MUPEUXNQ NFX2W29l\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? MWOyOVA5PTlyMh?=
ACHN MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX[wMlUuOTBizszN MV:wMVYh\A>? NU\XSHoyTE2VTx?= NUGzcW1wcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoruNlUxPjd5OEe=
Caki-2 M1XnTmNmdGxiVnnhZoltcXS7IFHzd4F6 MWewMlUuOTBizszN NIPWcZIxNTZiZB?= M3rlTmROW09? MmnIbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFPHcFUzPTB4N{e4Oy=>
A498 NWL2S2hLS2WubDDWbYFjcWyrdImgRZN{[Xl? M3zr[FAvPS1zMDFOwG0> M3\ORVAuPiCm NX63cJEyTE2VTx?= M17yfYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIPNboIzPTB4N{e4Oy=>
115 NFLUVFNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{D4blAvPS1zMDFOwG0> M{PyPFAuPiCm NFvMXGhFVVOR MmrLbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Ml3DNlUxPjd5OEe=
117 M{O1V2NmdGxiVnnhZoltcXS7IFHzd4F6 Mor3NE42NTFyIN88US=> M1G4NVAuPiCm NIW5S4JFVVOR Mlr0bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NFHoPFAzPTB4N{e4Oy=>
ACHN NH2z[|hHfW6ldHnvckBCe3OjeR?= NXLufo1jOC53L{GvOUDPxE1? MlzLOFghcA>? MUDEUXNQ M4Dze4xm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MW[yOVA3Pzd6Nx?=
Caki-2 MWTGeY5kfGmxbjDBd5NigQ>? Mnz6NE42NzFxNTFOwG0> MYq0PEBp MnnoSG1UVw>? MXvs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? M{nrUlI2ODZ5N{i3
A498 MofQSpVv[3Srb36gRZN{[Xl? NWHmSFZ6OC53L{GvOUDPxE1? NV34ZnJDPDhiaB?= M2LxT2ROW09? NI\pfnZt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MoPTNlUxPjd5OEe=
115 NHfwPGZHfW6ldHnvckBCe3OjeR?= MX:wMlUwOS93IN88US=> NIPZVGg1QCCq NXr4eWRrTE2VTx?= MV;s[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MljENlUxPjd5OEe=
ACHN NHjuUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTIOUDPxE1? MYG0PEBp NUPOXVRxTE2VTx?= MYHpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NWPRWYhzOjVyNke3PFc>
Caki-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3iyTVUh|ryP M1fXcVQ5KGh? NV;abmhXTE2VTx?= Ml\vbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MnTUNlUxPjd5OEe=
A498 MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HtdVUh|ryP MYO0PEBp NUTLUpduTE2VTx?= M3q5dIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> NYLkU3VXOjVyNke3PFc>
115 NGLib|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\NRVdbPSEQvF2= NFHPTpI1QCCq M{nOSGROW09? M4Xp[olv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> MmDiNlUxPjd5OEe=
ACHN MX3GeY5kfGmxbjDBd5NigQ>? NInyemM2KM7:TR?= M{HCR|Q5KGh? NYPsToNwTE2VTx?= NGTjVW1qdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NWXQb5hjOjVyNke3PFc>
Caki-2 NFvnWHpHfW6ldHnvckBCe3OjeR?= M16yOVUh|ryP Ml\zOFghcA>? NGfadnhFVVOR NFWzcVRqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg MkKzNlUxPjd5OEe=
A498 MmPGSpVv[3Srb36gRZN{[Xl? NUPsPJpDPSEQvF2= NWDSXFZHPDhiaB?= M4DQd2ROW09? MXvpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MW[yOVA3Pzd6Nx?=
115 NUfDdotvTnWwY4Tpc44hSXO|YYm= MknpOUDPxE1? NFrafFc1QCCq NYjOdVlmTE2VTx?= NVLXTGc2cW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MkDvNlUxPjd5OEe=
MOLM-13 NWD4S21STnWwY4Tpc44hSXO|YYm= MXS2xsDPxE1? M4S1NFAuQCCq NXXZNHJkTE2VTx?= MXfpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyNUOsJG1FVTJuIICyNUBidmRiYXPleJlt[XSnZDDwOVM> M4nVNVI1QDh3MEiy
MOLM-13 Ml;sSpVv[3Srb36gRZN{[Xl? MYO2xsDPxE1? NVHTcZlvPiCq NIT3SVhFVVOR M1KzRoVvcGGwY3XzJJRp\SCjY3X0fYxifGmxbjDv[kBpcXO2b37lJGgzSiCjbnSgbIVifCC|aH;jb{Bxem:2ZXnud{BJe3B{NzDhcoQhUHOyOUC= MUWyOFg5PTB6Mh?=
HepG2 NWLtVnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;BO|IhcA>? NFmzcFdFVVOR M{jyc2lEPTB;M{WuPFYhyrFiMj65JO69VQ>? MXuyOFg5PDhyOR?=
HepG2/As MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLVflk4OiCq M1XzVGROW09? NF\1WFJKSzVyPU[4MlE{KMLzIEmuOkDPxE1? MXWyOFg5PDhyOR?=
SMMC7721 M{HIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLzO|IhcA>? M{XHXmROW09? NUD6VmI1UUN3ME2zNU4zQCEEsTC0MlIh|ryP MmnjNlQ5QDR6MEm=
SMMC7721/Ac Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:0fmcxPzJiaB?= NHizV5FFVVOR NIPLfJBKSzVyPUW1MlIyKMLzIEWuNFMh|ryP NEfXWpIzPDh6NEiwPS=>
Huh-7 MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjLRZA4OiCq NF3WOYJFVVOR NID5NIFKSzVyPUOzMlk3KMLzIEOuPUDPxE1? NFHBUmUzPDh6NEiwPS=>
Hep3B MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr0O|IhcA>? MXXEUXNQ M1\Ic2lEPTB;MkCuNVghyrFiMT64OEDPxE1? MVuyOFg5PDhyOR?=
HepG2 NFTiPG5CeG:ydH;zbZMhSXO|YYm= MXnpcoR2[2W|IHHwc5B1d3Orcx?= MmfhNlQ5QDR6MEm=
SMMC7721 M2HWdGFxd3C2b4Ppd{BCe3OjeR?= NU\U[lZxcW6mdXPld{BieG:ydH;zbZM> NVXqO25vOjR6OES4NFk>
Huh-7 NXTpVWh[SXCxcITvd4l{KEG|c3H5 NH;Gfm1qdmS3Y3XzJIFxd3C2b4Ppdy=> NHfofHczPDh6NEiwPS=>
Hep3B MYfBdI9xfG:|aYOgRZN{[Xl? Moq2bY5lfWOnczDhdI9xfG:|aYO= MoW0NlQ5QDR6MEm=
U2OS  NIjMc2dHfW6ldHnvckBCe3OjeR?= M2KxSFIxKM7:TR?= NHzZeYEzPCCq M1\3TIlv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= M2XqcFI1QDZ5MkW5
AML2 NXTHUZhCSXCxcITvd4l{KEG|c3H5 MWqyM|ExKM7:TR?= M1j3TFI1NzR6IHi= NWGyeGdScW6mdXPld{BieG:ydH;zbZM> NY\2R4tzOjR4NUm3OFk>
MOML13 MVXBdI9xfG:|aYOgRZN{[Xl? NIXa[5IzNzFyIN88US=> NEnWfYUzPC92ODDo NYKx[ZVicW6mdXPld{BieG:ydH;zbZM> MY[yOFY2QTd2OR?=
AML2 NVHLSY1jTnWwY4Tpc44hSXO|YYm= MV:xNO69VQ>? MXOyM|QhcA>? NEnQdJdqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> M4fMSlI1PjV7N{S5
AML3 M{j4cGZ2dmO2aX;uJGF{e2G7 MVuxNO69VQ>? MVSyM|QhcA>? NGLxfZBqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> MoLXNlQ3PTl5NEm=
MOML13 NGnOXoNHfW6ldHnvckBCe3OjeR?= M1rrWVEx|ryP NEjnUWwzNzRiaB?= NHy3OWxqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NF;tUIYzPDZ3OUe0PS=>
BeWo NXKwU|V4TnWwY4Tpc44hSXO|YYm= NXH3eoVOOzBiwsXN NVTrZ4tiOjRiaB?= MUTpcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= M2TndlI1PDl6MUW0
BeWo M2LlemFxd3C2b4Ppd{BCe3OjeR?= NFXRZ4o{OCEEtV2= NF;j[WUzPCCq NHfhbYRqdmO{ZXHz[ZMh[XCxcITvd4l{ NXzxSo1GOjR2OUixOVQ>
OCI NEf0Z4VHfW6ldHnvckBCe3OjeR?= NH\XWZEyOCEQvF2= MV:yOEBp NVLWV2JJfXC{ZXf1cIF1\XNidHjlJHNQS1NvMTDlfJBz\XO|aX;u M4[1WlI1PDd|NU[y
MOLM NUD5UFF4TnWwY4Tpc44hSXO|YYm= NU\INFZWOTBizszN NETRSFIzPCCq MnL1eZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w NGPzWXozPDR5M{W2Ni=>
U2OS  MmfuSpVv[3Srb36gRZN{[Xl? MViyNEDPxE1? MWSyOEBp M1jiXolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? NXHXdJpDOjR|Nk[wNFc>
RKO MVzGeY5kfGmxbjDBd5NigQ>? M3\oUlIxKM7:TR?= NXPXT3U6OjRiaB?= M2jXXIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? MV6yOFM3PjByNx?=
U2OS  MnzOSpVv[3Srb36gRZN{[Xl? MVmyNEDPxE1? M1HzeVI1KGh? M4nnXolv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u NYnKXmdiOjR|Nk[wNFc>
RKO NFT2NVdHfW6ldHnvckBCe3OjeR?= M1nMU|IxKM7:TR?= MkL4NlQhcA>? MoTTbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= NIftb5QzPDN4NkCwOy=>
SMMC-7721  MnPNR4VtdCCYaXHibYxqfHliQYPzZZk> M{W2O|EvOjVvMkCg{txO MkL5NlQwPDhxN{KgbC=> NILxTJlFVVOR M1vUUolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M33VblI1Ojh4M{Gy
HuH-7 NYfCT3JIS2WubDDWbYFjcWyrdImgRZN{[Xl? MkfpNU4zPS1{MDFOwG0> NXu5WlVNOjRxNEivO|IhcA>? MW\EUXNQ M2j1dolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M3LxcFI1Ojh4M{Gy
SMMC-7721  MXjBdI9xfG:|aYOgRZN{[Xl? M1H6WlIxKM7:TR?= MVy0PEBp MorQSG1UVw>? NGrzdmRqdmS3Y3XzJIFxd3C2b4Ppdy=> MnG1NlQzQDZ|MUK=
HuH-7 M3HudWFxd3C2b4Ppd{BCe3OjeR?= MmflNlAh|ryP MYK0PEBp NUXDZpFSTE2VTx?= MUDpcoR2[2W|IHHwc5B1d3Orcx?= NXOwOmw6OjR{OE[zNVI>
SMMC-7721  Ml\1SpVv[3Srb36gRZN{[Xl? NWjob2s4OTBizszN MoPIN|YhcA>? NEHGOYlFVVOR Mnnh[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MYCyOFI5PjNzMh?=
HuH-7 M3HUVWZ2dmO2aX;uJGF{e2G7 M2DYdVExKM7:TR?= NIfuSos{PiCq MkHvSG1UVw>? MVTkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> MVuyOFI5PjNzMh?=
AT2 NYTsOHNzTnWwY4Tpc44hSXO|YYm= MYq1M|ExKM7:TR?= MnXxcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NHT6NYYzPDJ2MEKwNy=>
REH MWHGeY5kfGmxbjDBd5NigQ>? M3GyZlUwOTBizszN MV\s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NEKzNW8zPDJ2MEKwNy=>
UoCB6 M3zMT2Z2dmO2aX;uJGF{e2G7 NGL2Vno2NzFyIN88US=> NUTTVZV7dGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= M2D6TFI1OjRyMkCz
AT2 MXvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV[wMVI2KM7:TR?= NITXbXNqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MX2yOFI1ODJyMx?=
REH Ml71R4VtdCCYaXHibYxqfHliQYPzZZk> M1qwWlAuOjVizszN NV7TeGVycW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MVOyOFI1ODJyMx?=
UoCB6 MX3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX3Ib|RjOC1{NTFOwG0> MoPSbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MorVNlQzPDB{MEO=
A2780 NIfob5VHfW6ldHnvckBCe3OjeR?= NELEWIM2NzFyL{KwJO69VQ>? NXXiVHBnOjRiaB?= NW[yOnRpfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= NVHxc4V7OjRzM{[xOFc>
H460 NEe0ZZBHfW6ldHnvckBCe3OjeR?= MUG1M|ExNzJyIN88US=> NFjhRm0zPCCq MVv1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? Mnv4NlQyOzZzNEe=
Lovo  NULSV3F4TnWwY4Tpc44hSXO|YYm= NETrUHM2NzFyL{KwJO69VQ>? M1OzZlI1KGh? MmLleZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? MnnGNlQyOzZzNEe=
A2780 NFKyV3pCeG:ydH;zbZMhSXO|YYm= M3zoc|UwOTBxMkCg{txO NILie3IzPCCq MmXM[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> NVnxZYlFOjRzM{[xOFc>
H460 NIHxSZZCeG:ydH;zbZMhSXO|YYm= NXLUbFJRPS9zMD:yNEDPxE1? NYnMcZlUOjRiaB?= NGDMNY1mdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? NXq3XIw4OjRzM{[xOFc>
Lovo  MV3BdI9xfG:|aYOgRZN{[Xl? NEfZcYU2NzFyL{KwJO69VQ>? M1ftV|I1KGh? M4\FPYVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MmLQNlQyOzZzNEe=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Related Antibodies

Mdm2信号経路図

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID